IQVIA’s Doug Long: Adalimumab Biosimilars Provide More Opportunity for Price Discounts

The impact that the adalimumab biosimilars will have in 2023 is going to depend on when they all get to market, said Doug Long, MBA, vice president, industry relations, IQVIA.

The impact that the adalimumab biosimilars will have in 2023 is going to depend on when they all get to market, said Doug Long, MBA, vice president, industry relations, IQVIA.

Transcript

There are at least 7 adalimumab biosimilars expected to come to market in the United States in 2023. What impact do you think they might have in the short and long term?

Well, a lot depends on how much the originator protects the franchise. And, usually, they protect the franchise with either rebates or they cut the price. But nevertheless, is that the cost of autoimmune drugs are going to go down, because of what the manufacturers do and what the biosimilar manufacturers do. And again, it depends.

I think Amgen has 5 months' exclusivity or something like that. So, it depends on when they all hit. So, the more competition there is, the more chance there is for, you know, price discounting.